Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

CRISPR-Cas9 (Active) Protein

Spezies: Streptococcus pyogenes Wirt: Escherichia coli (E. coli) Recombinant > 95 % pure as determined by SDS-PAGE with Coomassie Blue detection. IVCA, IVGE, MI, REP, T Active
Produktnummer ABIN3071566
  • Target
    CRISPR-Cas9
    Protein-Typ
    Recombinant
    Biologische Aktivität
    Active
    Spezies
    • 6
    • 1
    Streptococcus pyogenes
    Quelle
    • 7
    Escherichia coli (E. coli)
    Applikation
    In vitro Cleavage Assay (IVCA), In vivo Gene Editing (IVGE), Microinjection (MI), RNA Electroporation (REP), Transfection (T)
    Spezifität
    Activity test
    Cas9 site-specific digestion:
    We used in vitro digestion of a linearized plasmid to determine the activity of the Cas9 nuclease. It is a sensitive assay for GenCrispr Cas9 quality control. The linearized plasmid containing the target site:
    (CATCATTGGAAAACGTTCTT)
    can be digested with gRNA:
    (CAUCAUUGGAAAACGUUCUUGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUUUU)
    and GenCrispr Cas9. Two cleavage DNA fragments (812 bp and 1898 bp) are determined by agarose gel electrophoresis. A 20 μL reaction in 1xCas9 Nuclease Reaction Buffer containing 160 ng linearized plasmid, 40 nM gRNA and 20 nM GenCrispr Cas9 for 2 hour at 37 °C results in 90 % digestion of linearized plasmid as determined by agarose gel electrophoresis.
    Produktmerkmale
    GenCrispr Cas9-C-NLS is produced by expression in an E. coli strain carrying a plasmid encoding the Cas9 gene from Streptococcus pyogenes with a C terminal nuclear localization signal (NLS).
    Aufreinigung
    purified
    Reinheit
    > 95 % pure as determined by SDS-PAGE with Coomassie Blue detection.
    Endotoxin-Niveau
    Endotoxin level is <0.1eu/ug test by gel-clot method: limit test
    Bestandteile
    GenCrispr Cas9-C-NLS
    10X Reaction Buffer
  • Applikationshinweise
    Screening the highly efficient and specific targeting gRNAs using in vitro DNA cleavage.
    In vivo gene editing combined with specific gRNA by electroporation or injection.
    Kommentare

    1. DNA-free: no external DNA added to system.
    2. High cleavage efficiency: NLS ensures the entry of Cas9 protein into nuclei.
    3. Low off target: transient expression of Cas9 nuclease.
    4. Time-saving: no need for transcription and translation.

    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Konzentration
    4 mg/mL
    Buffer
    10X Reaction Buffer: 200 mM HEPES, 1M NaCl, 50 mM MgCl2, 1 mM EDTA, pH 6.5 at 25 °C.
    1X Storage Buffer: 20 mM Tris, 600 mM NaCl, 0.1 mM EDTA,1 mM DTT,50 % Glycerol PH 7.4 at 25 °C)
    Konservierungsmittel
    Dithiothreitol (DTT)
    Vorsichtsmaßnahmen
    This product contains Dithiothreitol (DTT): a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Lagerung
    -20 °C
    Informationen zur Lagerung
    GenCrispr Cas9-C-NLS nuclease is supplied with 1X storage buffer (20 mM Tris, 600 mM NaCl, 0.1 mM EDTA, 1 mM DTT, 50% Glycerol PH 7.4 at 25°C) and recommended to be stored at -20°C.
    Diluent Compatibility: Diluent Buffer: 300 mM NaCl, 10 mM Tris-HCl, 0.1 mM EDTA, 1 mM DTT, 500 μg/ml BSA and 50% glycerol. (pH 7.4 at 25°C).
  • Target
    CRISPR-Cas9
    Andere Bezeichnung
    Cas9-C-NLS Nuclease
    Hintergrund
    Cas9 nuclease is an RNA-guided endonuclease that can catalyze cleavage of double stranded DNA. This kind of targeted nuclease is a powerful tool for genome editing with high precision. Cas9 protein forms a very stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component of the CRISPR/Cas9 system. The Cas9 RNP complex can localize to the nucleus immediately upon entering the cell with the addition of a nuclear localization signal (NLS). There is no requirement for transcription and translation compared with mRNA or plasmid systems. Additionally, the Cas9 RNP complex is rapidly cleared from the cell minimizing the chance of off-target cleavage when compared to other systems (Kim, et al. 2014). This DNA-free system avoids the risk of inserting foreign DNA into the genome, which can be quite useful for gene editing-based disease therapy. GenScript has developed a Cas9-C-NLS nuclease which contains a nuclear localization sequence (NLS) on the C-terminus of the protein to meet all the researchers' requirements (e.g. in vitro cleavage assay, RNP complex transfection, and micro injection).
Sie sind hier:
Kundenservice